|Hospital:||Institut Gustave Roussy|
|Patients: This Phase II study involved 70 patients with malignant pleural mesothelioma; 51 men and 19 women. Fifty-five patients had not received prior chemotherapy.|
Treatment: The treatment consisted of the drug raltitrexed (tomudex) and the chemotherapy agent, oxaliplatin (eloxatin).
Toxicity: Twenty patients withdrew from the treatment because of adverse events. There was one grade 4 event, asthenia. In addition, grade 3 toxicities included: nausea, paraesthesia, weight decrease, ALT and AST increase, vomiting, anorexia, hematologic, and abdominal pain.
Results: Overall median survival was 32 weeks (7.4 months).
Support: One or more of the study’s authors is affiliated with AstraZeneca, the manufacturer of tomudex.
Correspondence: K. Fizazi, MD